The Role of Flavin-Containing Monooxygenase (FMO) in the Metabolism of Tamoxifen and Other Tertiary Amines

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Drug metabolism reviews (Softcover ed.)

• Publication date

  2006-01-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1080/03602530600569919PMID 16684653
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aryl Hydrocarbon Receptor Regulates Distinct Dioxin-Dependent and Dioxin-Independent Gene Batteries

  2006cited by this paper
• Discovery of Novel Flavin-Containing Monooxygenase 3 (FMO3) Single Nucleotide Polymorphisms and Functional Analysis of Upstream Haplotype Variants

  2005cited by this paper
• FORMATION OF TAMOXIFEN-DNA ADDUCTS VIA O-SULFONATION, NOT O-ACETYLATION, OF α-HYDROXYTAMOXIFEN IN RAT AND HUMAN LIVERS

  2005influential reference
• Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

  2005cited by this paper
• Haplotype and functional analysis of four flavin-containing monooxygenase isoform 2 (FMO2) polymorphisms in Hispanics

  2005cited by this paper
• OXIDATION OF TAMOXIFEN BY HUMAN FLAVIN-CONTAINING MONOOXYGENASE (FMO) 1 AND FMO3 TO TAMOXIFEN-N-OXIDE AND ITS NOVEL REDUCTION BACK TO TAMOXIFEN BY HUMAN CYTOCHROMES P450 AND HEMOGLOBIN

  2005influential reference
• Organ specificity of DNA adduct formation by tamoxifen and alpha-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment.

  2005cited by this paper
• Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen

  2005cited by this paper
• Human flavin-containing monooxygenase form 2 S-oxygenation: sulfenic acid formation from thioureas and oxidation of glutathione.

  2004cited by this paper
• Genetic Polymorphisms of Human Flavin Monooxygenase 3 in Sulindac-Mediated Primary Chemoprevention of Familial Adenomatous Polyposis

  2004cited by this paper
• Study on the Organoleptic Intensity Scale for Measuring Oral Malodor

  2004cited by this paper
• Evaluation of xenobiotic N- and S-oxidation by variant flavin-containing monooxygenase 1 (FMO1) enzymes.

  2004cited by this paper
• Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6

  2004influential reference
• Tamoxifen and Metabolite Concentrations in Serum and Breast Cancer Tissue during Three Dose Regimens in a Randomized Preoperative Trial

  2004cited by this paper
• DIFFERENCES IN FMO2*1 ALLELIC FREQUENCY BETWEEN HISPANICS OF PUERTO RICAN AND MEXICAN DESCENT

  2004cited by this paper
• Trimethylaminuria and a human FMO3 mutation database

  2003cited by this paper
• Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen.

  2003cited by this paper
• Genetic Variability at the Human FMO1 Locus: Significance of a Basal Promoter Yin Yang 1 Element Polymorphism (FMO1*6)

  2003cited by this paper
• CYP2D6-mediated catalysis of tamoxifen aromatic hydroxylation with an NIH shift: similar hydroxylation mechanism in chicken, rat and human liver microsomes

  2003cited by this paper
• Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans.

  2003cited by this paper
• Alpha-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes.

  2003cited by this paper
• Human Hepatic Flavin-Containing Monooxygenases 1 (FMO1) and 3 (FMO3) Developmental Expression

  2002cited by this paper
• The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes.

  2002cited by this paper
• Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA.

  2002cited by this paper
• AN OVERVIEW OF THE MECHANISM, SUBSTRATE SPECIFICITIES, AND STRUCTURE OF FMOs

  2002cited by this paper
• Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation.

  2002cited by this paper
• GENETIC POLYMORPHISMS OF FLAVIN-CONTAINING MONOOXYGENASE (FMO)

  2002cited by this paper
• Human flavin-containing monooxygenase (form 3): polymorphisms and variations in chemical metabolism.

  2002cited by this paper
• Trimethylaminuria: the fish malodor syndrome.

  2001influential reference
• Immunoquantitation of FMO1 in human liver, kidney, and intestine.

  2000cited by this paper
• Phenotypes of flavin-containing monooxygenase activity determined by ranitidine N-oxidation are positively correlated with genotypes of linked FM03 gene mutations in a Korean population.

  2000cited by this paper
• Flavin‐containing monooxygenase isoform specificity for the N‐oxidation of tamoxifen determined by product measurement and NADPH oxidation

  2000cited by this paper
• Concurrent flavin-containing monooxygenase down-regulation and cytochrome P-450 induction by dietary indoles in rat: implications for drug-drug interaction.

  2000cited by this paper
• The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy.

  1999cited by this paper
• The tamoxifen dilemma.

  1999cited by this paper
• Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins.

  1999cited by this paper
• Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3.

  1998influential reference
• The Flavin-containing Monooxygenase 2 Gene (FMO2) of Humans, but Not of Other Primates, Encodes a Truncated, Nonfunctional Protein*

  1998cited by this paper
• CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.

  1997cited by this paper
• Tamoxifen metabolism by microsomal cytochrome P450 and flavin-containing monooxygenase.

  1996cited by this paper
• Evidence that the catechol 3,4-Dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins.

  1996cited by this paper
• The molecular biology of the flavin-containing monooxygenases of man.

  1995cited by this paper
• Tissue-specific expression of flavin-containing monooxygenase (FMO) forms 1 and 2 in the rabbit.

  1995cited by this paper
• Structural and catalytic properties of the mammalian flavin-containing monooxygenase.

  1995cited by this paper
• A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes.

  1994cited by this paper
• Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes.

  1994cited by this paper
• The mammalian flavin-containing monooxygenases: molecular characterization and regulation of expression.

  1994cited by this paper
• Induction of tamoxifen-4-hydroxylation by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), beta-naphthoflavone (beta NF), and phenobarbital (PB) in avian liver: identification of P450 TCDDAA as catalyst of 4-hydroxylation induced by TCDD and beta NF.

  1994cited by this paper
• Induction of Tamoxifen-4-hydroxylation by 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), β-Naphthoflavone (βNF), and Phenobarbital (PB) in Avian Liver: Identification of P450 TCDDAA as Catalyst of 4-Hydroxylation Induced by TCDD and βNF

  1994cited by this paper
• Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation.

  1993cited by this paper
• Stereoselective metabolism of (S)-(-)-nicotine in humans: formation of trans-(S)-(-)-nicotine N-1'-oxide.

  1993cited by this paper
• Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation.

  1993cited by this paper
• Chemical, enzymatic, and human enantioselective S-oxygenation of cimetidine.

  1993cited by this paper
• Factors regulating the activity of the rabbit lung flavin-containing mono-oxygenase

  1991cited by this paper
• Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation.

  1991cited by this paper
• Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment.

  1991cited by this paper
• Flavin-containing monooxygenases: catalytic mechanism and substrate specificities.

  1988cited by this paper
• Chapter 9 – Microsomal Flavin-Containing Monooxygenase: Oxygenation of Nucleophilic Nitrogen and Sulfur Compounds

  1980cited by this paper
• Hepatic microsomal mixed-function amine oxidase.

  1978cited by this paper
• [14] Hepatic microsomal mixed-function amine oxidase

  1978cited by this paper
• Microsomal oxidase. IV. Properties of a mixed-function amine oxidase isolated from pig liver microsomes.

  1972cited by this paper

• A multi-channel microfluidic platform based on human flavin-containing monooxygenase 3 for personalised medicine

  2024cites this paper
• Practical Aspects of Flavin-Containing Monooxygenase-Mediated Metabolism.

  2024cites this paper
• Spontaneously hypertensive rats exhibit increased liver flavin monooxygenase expression and elevated plasma TMAO levels compared to normotensive and Ang II-dependent hypertensive rats

  2024cites this paper
• Flavin containing monooxygenase 2 regulates renal tubular cell fibrosis and paracrine secretion via SMURF2 in AKI-CKD transformation

  2023cites this paper
• Longitudinal dynamics of the tumor hypoxia response: From enzyme activity to biological phenotype

  2023influential citation
• FMO family may serve as novel marker and potential therapeutic target for the peritoneal metastasis in gastric cancer

  2023cites this paper
• Biomimetic Dynamic Kinetic Asymmetric N-Oxidation with H2O2 and O2

  2023cites this paper
• Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions

  2022cites this paper
• Indoles Derived From Glucobrassicin: Cancer Chemoprevention by Indole-3-Carbinol and 3,3'-Diindolylmethane

  2021cites this paper
• Human flavin-containing monooxygenase 1 and its long-sought hydroperoxyflavin intermediate.

  2021cites this paper
• FMO3 Gene

  2020cites this paper
• Production of drug metabolites by human FMO3 in Escherichia coli

  2020cites this paper
• Ligand stabilization and effect on unfolding by polymorphism in human flavin-containing monooxygenase 3.

  2020cites this paper
• Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease

  2020cites this paper
• N- and S-oxygenation activity of truncated human flavin-containing monooxygenase 3 and its common polymorphic variants.

  2020cites this paper
• Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen

  2019cites this paper
• FMO1 gene expression independently predicts favorable recurrence-free survival of classical papillary thyroid cancer.

  2019cites this paper
• Ancestral-sequence reconstruction unveils the structural basis of function in mammalian FMOs

  2019cites this paper
• In silico prediction of potential chemical reactions mediated by human enzymes

  2018cites this paper
• Xenobiotic metabolism in the fish hepatic cell lines Hepa-E1 and RTH-149, and the gill cell lines RTgill-W1 and G1B: Biomarkers of CYP450 activity and oxidative stress.

  2018cites this paper
• Binding of methimazole and NADP(H) to human FMO3: In vitro and in silico studies.

  2018cites this paper
• Flavin‐Containing Monooxygenase 3 Polymorphic Variants Significantly Affect Clearance of Tamoxifen and Clomiphene

  2018cites this paper
• Bioelectrochemical profiling of two common polymorphic variants of human FMO3 in presence of graphene oxide

  2017cites this paper
• An Investigation into the Prediction of In Vivo Clearance for a Range of Flavin-containing Monooxygenase Substrates

  2017cites this paper
• Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer

  2017cites this paper
• The Role of T-helper 17 and T-helper 22 Lymphocytes in Beta-Lactam Hypersensitivity

  2016cites this paper
• Human flavin-containing monooxygenase 3 on graphene oxide for drug metabolism screening.

  2015cites this paper
• SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma

  2015cites this paper
• Role of the Red Ginseng in Defense against the Environmental Heat Stress in Sprague Dawley Rats

  2015cites this paper
• Interactions of Endoxifen and other major metabolites of Tamoxifen with human sulfotransferases SULT2A1, SULT1E1, and SULT1A1*1 : implications for the therapeutic action and toxicity of Tamoxifen

  2014cites this paper
• Developmental Hepatic Pharmacology in Pediatrics

  2013cites this paper
• Differential gene expression in ERα-positive and ERα-negative breast cancer cells upon leptin stimulation

  2013cites this paper
• Development of a CD‐MEKC method for investigating the metabolism of tamoxifen by flavin‐containing monooxygenases and the inhibitory effects of methimazole, nicotine and DMXAA

  2013cites this paper
• An investigation into the contribution of flavin containing monooxygenases to the development and prevention of thiourea-induced pulmonary toxicity in the rat

  2013influential citation
• The Development, Validation and Implementation of a Broad-Based ADME Genotyping Assay into Research and Clinical Trials

  2012cites this paper
• Clinical Pharmacogenetics of Olanzapine : with Focus on FMO Gene Polymorphisms

  2012cites this paper
• Pharmacogenetics in Drug Metabolism: Role of Phase I Enzymes

  2012cites this paper
• Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide

  2012cites this paper
• Flavin monooxygenases, FMO1 and FMO3, not cytochrome P450 isoenzymes, contribute to metabolism of anti-tumour triazoloacridinone, C-1305, in liver microsomes and HepG2 cells

  2011influential citation
• Biocatalysis as an alternative for the production of chiral epoxides: A comparative review

  2011cites this paper
• Partial Inhibition of Estrogen-Induced Mammary Carcinogenesis in Rats by Tamoxifen: Balance between Oxidant Stress and Estrogen Responsiveness

  2011cites this paper
• Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques.

  2011cites this paper
• The Imidazoacridinone Antitumor Drug, C-1311, Is Metabolized by Flavin Monooxygenases but Not by Cytochrome P450s

  2011cites this paper
• Genetic variants of flavin-containing monooxygenases:consequences for drug metabolism

  2010cites this paper
• Monoamine Oxidases and Flavin-Containing Monooxygenases

  2010cites this paper
• Structural elucidation of N-oxidized clemastine metabolites by liquid chromatography/tandem mass spectrometry and the use of Cunninghamella elegans to facilitate drug metabolite identification.

  2010cites this paper
• The potential of knockout mouse lines in defining the role of flavin-containing monooxygenases in drug metabolism

  2010influential citation
• Direct electrochemistry of drug metabolizing human flavin-containing monooxygenase: electrochemical turnover of benzydamine and tamoxifen.

  2010cites this paper
• The Biochemistry of Drug Metabolism – An Introduction

  2009cites this paper
• Flavin-containing monooxygenases: mutations, disease and drug response.

  2008influential citation
• Cyclic Conversion of the Novel Src Kinase Inhibitor TG100435 and Its N‐Oxide Metabolite by Flavin‐Containing Monoxygenases and Cytochrome P450 Reductase

  2008cites this paper
• The Flavin-Containing Monoooxygenases (FMOs): Genetic Variation and its Consequences for the Metabolism of Therapeutic Drugs

  2007cites this paper
• Cyclic Conversion of the Novel Src Kinase Inhibitor [7-(2,6-Dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (TG100435) and Its N-Oxide Metabolite by Flavin-Containing Monoxygenases and Cytochrome P450 Reductase

  2007cites this paper
• Dietary trans 10, cis 12-conjugated linoleic acid reduces the expression of fatty acid oxidation and drug detoxification enzymes in mouse liver

  2007cites this paper
• Metabolism and Pharmacokinetics of a Novel Src Kinase Inhibitor TG100435 ([7-(2,6-Dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and Its Active N-Oxide Metabolite TG100855 ([7-(2,6-Dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrro

  2007cites this paper
• Flavin-containing monooxygenase 3 and human disease

  2007cites this paper
• CHARACTERIZATION OF BIOTRANSFORMATION SYSTEMS IN HUMAN CELLS FOCUS ON STEM CELLS AND THEIR PROGENY

  2007cites this paper
• Metabolism and Pharmacokinetics of a Novel Src Kinase Inhibitor TG100435 ([7-(2,6-Dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]- [4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and Its Active N-Oxide Metabolite TG100855 ([7-(2,6-Dichloro-phenyl)-5-methyl- benzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-py

  2007cites this paper
• BIOTRANSFORMATION SYSTEMS IN HUMAN CELLS

  2007cites this paper
• Linus Pauling Institute The OREGON STATE UNIVERSITY From the Director

  2006cites this paper